CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
376-390 of 1187
The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
MinuteCE®The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
A.J. Gelderblom, MD, PhD
Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
MinuteCE®Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
A.J. Gelderblom, MD, PhD
Michiel van de Sande, MD, PhD
Are You On Top of Pediatric Atopic Dermatitis? Expert Guidance for Leveraging the Latest Advances in Systemic Therapy
CME/CEAre You On Top of Pediatric Atopic Dermatitis? Expert Guidance for Leveraging the Latest Advances in Systemic Therapy
Peter A. Lio, MD
Wendy Smith Begolka, MBS
Elizabeth Swanson, MD, FAAD
All Sides of the Joint: Integrated TGCT Care Across Specialties
MinuteCE®All Sides of the Joint: Integrated TGCT Care Across Specialties
A.J. Gelderblom, MD, PhD
Michiel van de Sande, MD, PhD
Chelsea Cole, MD
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
MinuteCE®Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
A.J. Gelderblom, MD, PhD
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
MinuteCE®Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
A.J. Gelderblom, MD, PhD
- advertisement
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
MinuteCE®Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
A.J. Gelderblom, MD, PhD
Chelsea Cole, MD
A.J. Gelderblom, MD, PhD
Michiel van de Sande, MD, PhD
Chelsea Cole, MD
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
MinuteCE®The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
A.J. Gelderblom, MD, PhD
Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
MinuteCE®Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
A.J. Gelderblom, MD, PhD
- MinuteCE®
Clearing the Brain Fog: Innovations in the Treatment and Management of Hepatic Encephalopathy
Arun B. Jesudian, MD
Nancy S. Reau, MD
Current Treatment of Hepatic Encephalopathy: Is It Meeting Our Patients' Needs?
MinuteCE®Current Treatment of Hepatic Encephalopathy: Is It Meeting Our Patients' Needs?
Arun B. Jesudian, MD
- advertisement
Advances in the Treatment of Overt Hepatic Encephalopathy: What's in the Pipeline?
MinuteCE®Advances in the Treatment of Overt Hepatic Encephalopathy: What's in the Pipeline?
Arun B. Jesudian, MD
Nancy S. Reau, MD
Treatment of Hepatic Encephalopathy: Primary vs Secondary Prophylaxis
MinuteCE®Treatment of Hepatic Encephalopathy: Primary vs Secondary Prophylaxis
Arun B. Jesudian, MD
Nancy S. Reau, MD
Treatment of Hepatic Encephalopathy: When, What, How, and Why?
MinuteCE®Treatment of Hepatic Encephalopathy: When, What, How, and Why?
Arun B. Jesudian, MD
